Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alosetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 3/20 | 0.98 |
| ▸ | CASP6 | P55212 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.98 |
| ▸ | HTR2B | P41595 | 2/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.98 |
| ▸ | HTR2A | P28223 | 1/20 | 0.98 |
| ▸ | HTR2C | P28335 | 1/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.98 |
| ▸ | CD44 | P16070 | 1/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.40 |
| ▸ | HTR3B | O95264 | 2/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.40 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alosetron SCHEMBL29387635 | 1.00 | CASP6 (1.00) | CASP6KCNH2HTR3ACYP3A4CYP1A2 | |
| Alosetron SCHEMBL29377019 | 0.99 | KCNH2 (1.00) | CASP6KCNH2HTR3ACYP3A4CYP1A2 | |
| Alosetron SCHEMBL631 | 0.99 | KCNH2 (1.00) | CASP6KCNH2HTR3ACYP3A4CYP1A2 | |
| Alosetron SCHEMBL635233 | 0.97 | KCNH2 (0.96) | CASP6KCNH2HTR3ACYP3A4CYP1A2 | |
| Alosetron SCHEMBL850 | 0.94 | KCNH2 (0.90) | CASP6KCNH2HTR3ACYP3A4CYP1A2 | |
| SCHEMBL837 | 0.93 | KCNH2 (0.88) | CASP6KCNH2HTR3ACYP3A4CYP1A2 | |
| Alosetron SCHEMBL13345838 | 0.92 | KCNH2 (0.86) | CASP6KCNH2HTR3ACYP3A4CYP1A2 | |
| Alosetron SCHEMBL1046 | 0.92 | KCNH2 (0.85) | CASP6KCNH2HTR3ACYP3A4CYP1A2 | |
| Alosetron SCHEMBL1045 | 0.92 | KCNH2 (0.85) | CASP6KCNH2HTR3ACYP3A4CYP1A2 | |
| Alosetron SCHEMBL13345845 | 0.89 | KCNH2 (0.81) | CASP6KCNH2HTR3ACYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 615 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144776-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | ALTO NEUROSCIENCE, INC. (US) | 2026-05-28 | — | — | US | claimed |
| CN-106659789-B | CYP2J2 antagonists in the treatment of pain | 弗劳恩霍夫应用研究促进协会 | 2020-11-03 | — | — | CN | claimed |
| WO-2018039159-A1 | MUSCARINIC M2-ANTAGONIST COMBINATION | CHASE PHARMACEUTICALS CORPORATION (US) | 2018-03-01 | — | — | WO | claimed |
| WO-2017147104-A1 | MUSCARINIC M2-ANTAGONIST COMBINATIONS | CHASE PHARMACEUTICALS CORPORATION (US) | 2017-08-31 | — | — | WO | claimed |
| CN-106659789-A | Cyp2j2 antagonists in the treatment of pain | 弗劳恩霍夫应用研究促进协会 | 2017-05-10 | — | — | CN | claimed |
| US-20140322302-A1 | THERAPEUTIC PEPTIDES | COMBIMAB, INC (US) | 2014-10-30 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20120164139-A1 | Dopamine 3 receptor agonist and antagonist treatment of gastrointestinal motility disorders | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-06-28 | — | — | US | claimed |
| US-20100099669-A1 | Dopamine 3 receptor agonist and antagonist treatment of gastrointestinal motility disorders | PASRICHA PANKAJ JAY | 2010-04-22 | — | — | US | claimed |
| EP-2114389-A1 | METHODS AND COMPOSITIONS FOR TREATING AT LEAST ONE UPPER GASTROINTESTINAL SYMPTOM | AGI Therapeutics Research Limited (IE) | 2009-11-11 | — | — | EP | claimed |
| WO-2006052626-A2 | DOPAMINE 3 RECEPTOR AGONIST AND ANTAGONIST TREATMENT OF GASTROINTESTINAL MOTILITY DISORDERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-05-18 | — | — | WO | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1603544-A1 | TREATMENT OF INTESTINAL CONDITIONS WITH N-2,3,3-TETRAMETHYLBICYCLO 2.2.1 HEPTAN-2-AMINE | AGI Therapeutics Ltd. (IE) | 2005-12-14 | — | — | EP | claimed |
| US-20040209961-A1 | Treatment of intestinal conditions with N-2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine | AGI THERAPEUTICS LIMITED (IE) | 2004-10-21 | — | — | US | claimed |
| WO-2004080446-A1 | TREATMENT OF INTESTINAL CONDITIONS WITH N-2,3,3-TETRAMETHYLBICYCLO[2.2.1]HEPTAN-2-AMINE | AGI THERAPEUTICS LTD. (US) | 2004-09-23 | — | — | WO | claimed |
| WO-2003100091-A1 | MEANS AND METHODS FOR IMPROVED TREATMENT USING 'SETRONES' | EPIDAUROS BIOTECHNOLOGIE AG (DE) | 2003-12-04 | — | — | WO | claimed |
| CN-1281357-A | Medicaments | GLAXO GROUP LTD (GB) | 2001-01-24 | — | — | CN | claimed |
| US-5360800-A | Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives | GLAXO GROUP LIMITED (GB) | 1994-11-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144776-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | SLC6A3, SLC6A4, HTR4 | HTR3A 4/4885CASP6 2120/4885KCNH2 1065/4885 |
| US-20140322302-A1 | THERAPEUTIC PEPTIDES | VIP, GMPS, PDE3A | HTR3A 1293/4885CASP6 1938/4885KCNH2 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.